ÂÜÀòÂÒÂ×

Dr. Linton co-founded Iridia in 2016 and led the company as CEO and President through Q4 2019. During that time he oversaw the assembly of the company’s Board, Advisory Board, operating team, and financial management team. He was responsible for raising the Company’s $8M Series A capital, a team member in the recent $24M Series A-3/A-4 financing, and continues to serve as an executive advisor to the CEO. Dr. Linton has over twenty-five years of entrepreneurial and executive experience in the biotechnology space, co-founding five previous companies, as well as leading the fundraising and business development efforts in several companies. He has successfully raised over $350M in the capital, negotiated over $400M in deals, and has had multiple successful exits including Protometrix, Axiom Biotechnologies and Owl Biomedical.

Early in his career, Dr. Linton was a post-doctoral fellow at Merck Research Laboratories working on molecular cloning of genes responsible for FK-506-induced immunosuppression. He obtained his M.B.A. from the University of California at Davis and his Ph.D. in Molecular Genetics from Emory University.